Navigation Links
Role Of MicroRNAs In Angiogenesis Researched

According to recent research, MicroRNAs are fine targets for future therapies.Researchers belonging to the University of Pennsylvania School of Veterinary //Medicine have demonstrated how microRNA molecules are responsible for the growth of blood vessels in a human colon cancer model. This process, known as angiogenesis, is a result of the ravenous cancer cells using blood vessels to gorge on a steady supply of nutrients and oxygen.

The findings, which appear in the online version of Nature Genetics, suggest that these MicroRNAs might also be a good target for future therapeutics designed to slow the growth of cancer cells.

"These findings also uncover a new role for a well-known cancer-causing gene called MYC," said Andrei Thomas-Tikhonenko, professor in Penn Vet's Department of Pathobiology. "We have discovered that, within a tumor cell, one of the tasks of MYC is to turn loose a particular set of MicroRNAs, which then becomes responsible for promoting the growth of new blood vessels that nourish the tumor."

MicroRNAs are, as the name implies, short strands of RNA. During the last few years, microRNAs have been found to have a significant role in the process by which genes are translated into proteins. Clusters of microRNA have been "caught" associated with messenger RNA, the intermediary molecule that "instructs" the cell's protein-building machinery. In particular, MicroRNAs help determine the life span of messenger RNA and, therefore, how many copies of a protein can be made from a single messenger RNA molecule.

The Penn researchers discovered the role of microRNAs in angiogenesis while studying what makes MYC unique among other cancer-causing genes, or oncogenes. In particular, they were curious why cells with hyperactive MYC don't accumulate particularly fast in Petri dishes yet grow explosively in animal models for the disease.

"There are obviously no blood vessels in a petri dish, so the angiogen ic properties of the MYC gene are not advantageous," said Michael Dews, senior researcher in the Thomas-Tikhonenko lab. "In the incubator, the cancer cells grow at normal rates, but in the mouse model you see them recruiting a lot of blood vessels and really taking off. Curiously, this is not the case with some other oncogenes. So, what makes MYC special?"

The MYC protein is known to have a role in determining how certain genes are transcribed into messenger RNAs. To understand the role of MYC in angiogenesis, the Penn researchers used micro array technology to screen MYC-positive and MYC-negative cancerous cells for the presence or absence of 192 known pro- and anti-angiogenesis molecules. They found that, while MYC did not lead to excessive amounts of pro-angiogenesis molecules, it did seem to depopulate an entire family of anti-angiogenesis molecules related to the so-called thrombospondin-1 protein. MYC effectively disabled the brakes that slow angiogenesis.

The Thomas-Tikhonenko lab had previously demonstrated that MYC decreases the lifespan of the messenger RNA encoding thrombospondin. Since microRNAs had emerged as important regulators of messenger RNA stability, the Penn researchers believed there was a good chance of a MYC-microRNA-thrombospondin connection.

Their long-standing collaborator Chi Dang, a professor at Johns Hopkins University, suggested talking to another Hopkins researcher, Joshua Mendell. Mendell had extensive expertise in microRNA function and just a few months ago teamed up with Dang to identify MYC as an important regulator of microRNAs. The new collaboration between the Thomas-Tikhonenko and Mendell laboratories identified a missing link between MYC and thrombospondin, which indeed turned out to be a microRNA cluster designated miR-17-92. In the key experiment the researchers engineered poorly angiogenic tumor cells to produce copious amounts of miR-17-92. These modified cells, just like cells with hyp eractive MYC from earlier experiments, formed much larger tumors with better blood supplies.

"It has become increasingly clear that microRNAs are abnormally expressed in many types of cancer and select microRNAs have been demonstrated to act as a new type of oncogene," Mendell said. "As such, microRNAs represent an entirely new class of potential targets for cancer therapy." According to Mendell, an "anti-sense" version of miR-17-92 could bind to miR-17-92, thereby canceling its effects. If it is possible to deliver "regular" miR-17-92 to increase angiogenesis, as was demonstrated in the Nature Genetics paper, it may be possible to deliver anti-sense miR-17-92 to decrease angiogenesis and tumor growth.

source:eurekalert
'"/>




Related medicine news :

1. MicroRNAs Can Be Tumor Suppressors
2. New Angiogenesis Finding May Help Fight Cancer Growth
3. A Combination Of Drugs Used For Anti-Angiogenesis And Apoptosis More Effective
4. Anti-fungal Drug Block Angiogenesis
5. Causes of Sudden Infant Death Researched
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: